Inicio・Lista de Acciones・Krystal Biotech Inc

Krystal Biotech Inc

Abierto

SectorSanidad

338.13 1.38

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

323.5

Máximo

341.68

Métricas clave
By Trading Economics
Ingresos	4.5M 56M
Ventas	9.3M 116M
P/B Media del Sector	45.472 62.58
BPA	1.83
Margen de beneficios	48.069
Empleados	295
EBITDA	24M 63M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+5.85% upside

Dividendos
By Acuity
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2B 10B
Apertura anterior	336.75
Cierre anterior	338.13

Noticias sobre sentimiento de mercado

By Acuity

50%

156 / 340 Clasificación en Healthcare

Krystal Biotech Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20 jul 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Comparación entre iguales

Cambio de precio

Krystal Biotech Inc previsión

Precio Objetivo

By TipRanks

5.85% repunte

Estimación a 12 Meses

Media 358.89 USD 5.85%

Máximo 474 USD

Mínimo 284 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Krystal Biotech Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Krystal Biotech Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

156 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.